Delivering N-acetylcysteine directly to the brain to help treat Parkinson's Disease
Circumventing the pharmacokinetic/pharmacodynamic limitations of antioxidant therapy for Parkinson's Disease by nose to brain delivery of N-acetylcysteine
This study is exploring a new way to deliver a helpful antioxidant called N-acetylcysteine (NAC) directly to the brain to see if it can help slow down Parkinson's Disease, and it's designed for people living with this condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Neuronasal INC NIH-funded |
| Lab location | 1 site (Wexford, United States) |
| Project ID | NIH-10920628 on NIH RePORTER |
What this research studies
This research investigates a new method of delivering N-acetylcysteine (NAC), an antioxidant, directly to the brain to potentially slow the progression of Parkinson's Disease (PD). The approach aims to overcome the limitations of traditional NAC delivery methods, which may not effectively reach the brain. By using a nose-to-brain delivery system, the study seeks to enhance the bioavailability of NAC, targeting the neurodegenerative processes associated with PD. Patients with PD may benefit from this innovative treatment strategy that focuses on neuroprotection.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Parkinson's Disease, particularly those experiencing early to moderate symptoms.
Not a fit: Patients with advanced Parkinson's Disease or those who do not respond to antioxidant therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic option that may slow down the progression of Parkinson's Disease and improve patients' quality of life.
How similar studies have performed: While the use of NAC has been studied in various contexts, this specific nose-to-brain delivery method is novel and has not been extensively tested in Parkinson's Disease.
Where this research is happening
Wexford, United States
- Neuronasal INC — Wexford, United States (Active)
Researchers
- Principal investigator: Greene, Douglas — Neuronasal INC
- Study coordinator: Greene, Douglas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.